Revelation Biosciences Inc (REVB) Actualités

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of...

Form 8-K - Current report

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of...

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Current Report Filing (8-k)

false00018105600001810560revb:CommonStockParValue0001PerShareMember2023-06-292023-06-2900018105602023-06-292023-06-290001810560revb:RedeemableWar...

Form 8-K - Current report

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of...

Additional Proxy Soliciting Materials (definitive) (defa14a)

    UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C...